
What we do
We exist to advance medical research, improve human health and change people’s lives. You can help us do it.
Respiratory diseases
A fellowship to fill the gap in the understanding of the factors that drive idiopathic pulmonary fibrosis (IPF). Alveolar cells in lungs are important for the breathing process and are injured in IPF. Dr Conforti’s research will look at the interaction between alveolar cells and other lung cells called fibroblasts to determine if alveolar cells can be protected from their damaging effects.
We awarded Dr Franco Conforti from the University of Southampton a fellowship to fill the gap in the understanding of the factors that drive idiopathic pulmonary fibrosis (IPF). Alveolar cells in lungs are important for the breathing process and are injured in IPF. Other cells in lungs, fibroblasts, which are usually responsible for promoting wound healing become abnormal in IPF and produce excess scar tissue.
Fibroblasts are likely to produce mediators that damage the alveolar cells further, but little is known about how these cells interact to cause abnormal wound-healing and exaggerated scarring. Dr Conforti’s research will look at the interaction and try to determine if alveolar cells can be protected from the damaging effects of the fibroblasts.
Idiopathic pulmonary fibrosis (IPF) is an incurable rare lung disease. 15,000 people in the UK are living with IPF. The key feature of IPF is the irreversible build-up of dense scar tissue within the air spaces of the lungs, which leads to breathlessness and ultimately respiratory failure. The causes are unknown, and current treatments do not stop the progression of disease, only slow it down.
We fund and support the most promising health research wherever we discover great opportunities that are not being pursued. We use our donations responsibly and ensure we make the greatest impact where it is most needed.
Support the power of science